# David Yang

> David Yang is a Series A investor at Abu Dhabi Investment Authority backing Life Science. See 1 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Abu Dhabi Investment Authority](https://shizune.co/investors/profile/abu-dhabi-investment-authority)
- Total investments: 1
- Last investment: Feb 2025
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/pub/david-yang/0/724/1a3
- X (Twitter): http://twitter.com/davidkyang
- Facebook: http://www.facebook.com/davidkyang

David Yang is a Series A investor at Abu Dhabi Investment Authority focused on Life Science and Biotechnology. David Yang has over 10 years of experience in healthcare. Prior to joining Essex Woodlands, Mr. Yang was a Principal with Warburg Pincus in China where he was a key member of their healthcare team since 2007. He worked particularly closely with Warburg Pincus investments in Lepu Medical, and CITIC Pharmaceuticals.Prior to joining WarburgPincus, he worked at Morgan Stanley and Fidelity Investments in the US, and with McKinsey & Co. in Shanghai. Mr. Yang obtained an MBA from Columbia Business School. Mr Yang joined Essex Woodlands as Managing Director and co-head of the Shanghai office in April 2012.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Life Science | 1 | 100% |
| Biotechnology | 1 | 100% |
| Pharmaceutical | 1 | 100% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Atrandi Biosciences | Atrandi Biosciences, founded in 2016, is a pioneering life sciences tool company transforming single-cell analysis with its patented Semi-Permeable Capsule (SPC) technology. This next-generation technology isolates tens of thousands of single cells within discrete, permeable compartments, allowing bulk reactions to proceed as usual while preservingsingle-cell resolution. SPCs have already unlocked previously inaccessible applications, such as high-throughput microbial and eukaryotic genomics, and are poised to enable true single-cell multiomics. Headquartered in Vilnius, Lithuania, Atrandi’s name, meaning “you discover” in Lithuanian, embodies the company’s mission to empower scientists to uncover the unknown and make groundbreaking discoveries. | $25M | Series A | Feb 18, 2025 |  |

1 of 1 investments shown.

## Co-investors
- [GRIDS Capital](https://shizune.co/investors/profile/grids-capital) — VC Fund, 1 deal together
- [Metaplanet](https://shizune.co/investors/profile/metaplanet-holdings) — VC Fund, 1 deal together
- [Microsoft](https://shizune.co/investors/profile/microsoft) — VC Fund, 1 deal together
- [Practica Capital](https://shizune.co/investors/profile/practica-capital) — VC Fund, 1 deal together
- [Vsquared Ventures](https://shizune.co/investors/profile/vsquared-ventures) — VC Fund, 1 deal together

## About Abu Dhabi Investment Authority

VC Fund · Abu Dhabi, United Arab Emirates

Abu Dhabi Investment Authority is an investment management agency investing funds on behalf of the Government of Abu Dhabi. ADIA does not directly to manage or take an operational role in the companies in which it invests but through it's PPP Representative Eiosoft Capital Group LLC.

5 contacts available at Abu Dhabi Investment Authority.

| Name | Title | Profile |
| --- | --- | --- |
| Andrew Kripke | Director, Portfolio Manager - US Team | https://shizune.co/investors/profile/andrew-kripke |
| David Yang | Head of China Private Equity | https://shizune.co/investors/profile/david-yang-3 |
| Han Huang | Investment Risk Manager | https://shizune.co/investors/profile/han-huang |
| Jan Schuster | Portfolio Manager - Private Equity Division | https://shizune.co/investors/profile/jan-schuster |
| Jeroen Verleun | Investment Manager External Fixed Income | https://shizune.co/investors/profile/jeroen-verleun |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does David Yang invest in?

David Yang invests primarily in Life Science, Biotechnology and Pharmaceutical startups, most often at Series A stage. Most of the 1 investments tracked by Shizune back companies in Lithuania. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did David Yang last invest?

The most recent investment recorded for David Yang closed in Feb 2025. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co